Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
This study was terminated on 08 Nov 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of osteoarthritis (OA) of the knee according to American College of Rheumatology (ACR) criteria with a Kellgren- Lawrence score of greater than or equal to 2
18 years of age or greater
Two methods of birth control one of which must be barrier if of childbearing potential
Willing to discontinue pain medication except as permitted per protocol
You may not be if
Pregnancy or wishing to be pregnant during the course of the study, lactating women
Body Mass Index (BMI) greater than 39
Clinically significant cardiac, neurological, psychiatric conditions and other conditions that are excluded by the protocol.
Previous exposure to a Nerve Growth Factor (NGF) antibody
